Hepatitis C pada Thalassemia mayor: pengaruh Iron Overload pada perjalanan penyakit
Sari
Indonesia sebagai negara yang termasuk dalam thalassemia belt juga mengalami masalah
dan komplikasi yang timbul akibat penyakit tersebut. Masalah klasik thalassemia adalah
pemberian transfusi darah berulang yang mengakibatkan penularan penyakit melalui
transfusi darah seperti hepatitis C, di samping penimbunan besi di dalam berbagai
organ dan jaringan. Penimbunan besi yang berlebihan (iron overload) akan mengakibatkan
penurunan fungsi sistim imun pada pasien thalassemia yang juga akan berpengaruh
pada perjalanan penyakit apabila terinfeksi oleh mikro organisme patogen. Pasien
thalassemia yang terinfeksi virus hepatitis C (VHC) akan mengalami kerusakan hati
baik akibat infeksi VHC maupun akibat terjadinya penimbunan besi karena mendapat
tranfusi darah berulang tanpa pemberian kelasi besi yang adekuat. Pengobatan VHC
pada thalassemia sampai saat ini belum ada yang adekuat sehingga uji tapis merupakan
instrumen yang penting dalam mencegah penyakit tersebut.
Kata Kunci
Teks Lengkap:
PDFReferensi
Higgs DR, Thein SL, Wood WG. /The biology of the
thalassaemia. Dalam: Weatherall DJ, Clegg JB,
penyunting. The thalassaemia syndromes. Edisi keempat.
Edinburgh: Blackwell Science, 2001. h. 65-237.
Olivieri NE. The b-thalassemias. N Engl J Med 1999;
:99-109.
Tobler LH, Busch MP. History of posttransfusion hepatitis.
Clin Chem 1997; 43:1487-93.
Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The
risk of transfusion-transmitted viral infection. N Engl J
Med 1996; 334:1685-90.
Li CK, Chik KW, Lam CWK, To KF, Yu SCH, Lee V.
Liver disease in transfusion dependent thalassaemia major.
Arch Dis Child 2002; 86:344-7.
Prati D, Zanella A, Farma E, De Mattei C, Bosoni P,
Zappa M. A multicenter prospective study on the risk
of acquiring liver disease in anti-hepatitis C virus negative
patients affected from homozygous b-thalassemia.
Blood 1998; 92:3460-4.
Bronkovsky HL, Banner BF, Rothman AL. Iron and
chronic viral hepatitis. Hepatology 1997; 25:759-68.
Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW,
Houghton M. Isolation of a cDNA clone derived from
blood-borne non-A, non-B viral hepatitis genome. Science
; 244:359-62.
Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG,
Purcell RH, dkk. An assay for circulating antibodies to a
major etiologic virus of human non-A, non-B hepatitis.
Science 1989; 244:362-4.
Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic
differences and temporal trends. Semin Liver Dis
; 20:1-16.
Sulaiman A, Julitasari, Sie A, Rustam M, Melani W,
Corwin A, dkk. Prevalence of hepatitis B and C in healthy
Indonesian blood donors. Trans R Soc Trop Med Hyg
; 89:167-70.
Lai ME, De Virgilis S, Argiolu F, Farci P, Mazzoleni AP,
Lisci V, dkk. Evaluation of antibodies to hepatitis C virus
in a long-term prospective study of posttransfusion
hepatitis among thalassemic children: comparison between
first-and second- generation assay. J Pediatr
gastroenterol Nutr 1993; 16:458-64.
Arief S. Hepatitis C virus. Dalam: Soetjiningsih, Sukardi
R, Subanada IB, Sanjajayaputra IGN, Mahalini DS,
penyunting. Proceedings of 12th the national congress of
child health; 2002 Jun 30-Jul 4; Bali, Indonesia. Bali; Dept
of child health University Udayana; 2002. h. 409-18.
Wiharta AS, Timan IS. Hepatitis C pada penderita
talasemi. Dalam: Wiharta AS, Zulkarnain Z,
Purnamawati SP, penyunting. Naskah lengkap PKB
IKA XXVII. Hepatologi anak masa kini; 1992 Nov 6-7; Jakarta. Jakarta: Balai Penerbit FKUI; 1992. h.
-169.
Lauer GM, Walker BD. Hepatitis C virus infection. N
Engl J Med 2001; 345:41-52.
Rundles SC, Giardina PJ, Grady RW, Califano C,
McKenzie P, de Sousa M. Effect of transfusional iron
overload on immune response. J Infect Dis 2000;
suppl:115S-21S.
Akbar AN, Bocarsly AF, de Sousa M, Gardina PJ,
Hilgartner MW, Grady RW. Decreased natural killer
activity in thalassemia major: a possible consequence of
iron overload. J Immunol 1986; 136:1635-1640.
Weiss G, Umlauft F, Urbanek M, Herold M, Lovevsky
M, Offner F, dkk. Association between cellular immune
effector function, iron metabolism, and disease activity
in patients with chronic hepatitis c virus infection. J Infect
Dis 1999; 180:1452-1458.
Esteban JI, Gonzales A, Hernandez JM, Viladomiu
L, Sanchez C, Talavera JL, dkk. Evaluation of antibodies
to hepatitis C virus in a study of transfusionassociated
hepatitis. N Engl J Med 1990; 323:1107-
Liang TJ, Reherman B, Seef LB, Hoofnagle JH. Pathogenesis,
natural history, treatment and prevention of
hepatitis C. Ann Intern Med 2000; 132:296-305.
Farci P, Purcell RH. Clinical significance of hepatitis C
virus genotype and quasispecies. Semin Liv Dis 2000;
:103-122.
Honda M, Kaneko S, Sakai A, Unoura M, Murakami S,
Kobayashi K. Degree of diversity of hepatitis C virus
quasispecies and progression of liver disease. Hepatology
; 20:1144-1151.
Purcell R. The hepatitis C virus: overview. Hepatology
;3. suppl1:11S-4S.
Forns X, Bukh J. The molecular biology of hepatitis C
virus. Genotypes and quasispecies. Clin Liver Dis 1999;
:693-716.
Bruno S, Silvi E, Crosignani A, Borzio F, Leandro G, Bono
F, dkk. Hepatitis C virus genotypes and risk of hepatocellular
carcinoma: a prospective study. Hepatology 1997;
:754-758.
Lesmana LA, Sulaiman A, Noer MS, Tsuda F, Okamoto
H. Hepatitis C virusgenotypes and co-infection with GB
virus C in patients with anti-HCV-positive chronic Liver
disease in Jakarta, Indonesia. International Hepatologi
Communication 1996; 6:16-23.
Schwimmer JB, Balistreri WF. Transmission, natural history
, and treatment of hepatitis C virus infection in the
pediatric population. Semin Liv Dis 2000; 20:37-46.
Gruner NH, Gerlach TJ, Jung MJ, Diepolder HM,
Schirre CA, Schraut WW. Association of hepatitis C virus
specific CD8 T cells with viral clearance in acute
hepatitis C.J Infect Dis 2000; 181:1528-36.
Large MK, Kittlesen DJ, Hahn YS. Suppresion of host
immune response by the core of protein hepatitis C virus:
possible implication for hepatitis C virus persistence.
J immunol 1999; 162:931-8.
Bronkovsky HL, Lambrecht RW. Patophysiology of liver
disease. Iron-induced liver injury. Clin Liver Dis 2000;
:409-29.
Hoofnagle JH. Course and outcome of hepatitis C.
Hepatology 2002; 36:21S-29S.
Tong MJ, El Farra NS, Reiks A. Clinical outcomes after
transfusion associated hepatitis C. N Engl J Med. 1995;
:1463-66.
Harris HE, Ramsay ME, Andrews N. Clinical course of
hepatitis C virus during the first decade of infection:
cohort study. Br Med J 2002; 324:3-8.
Vogt M, Lang T, Frosner G, Klinger C, Sendl AF, Zeller
A, dkk. Prevalence and clinical outcome of hepatitis C
infection in children who underwent cardiac surgery
before the implementation of blood-donor screening. N
Engl J Med 1999; 341:886-70.
Resti M, Azzari C, Rossi ME, Vullo C, Zammarchi E,
Vierucci A. Hepatitis C virus antibodies in a long-term follow-
up of beta-thalassaemic children with acute and chronic
non-A non-B hepatitis. Eur J Pediatr 1992; 151:573-
[Abstrak].
Andrews NC. Disorders of iron metabolism. N Engl J
Med 1999; 341:1986-95.
Kushner JP, Porter JP, Olivieri NF. Secondary iron overload.
Haematology 2001:47-61. didapat dari http://
www.asheducationbook.org/cgi/content/full/2001/1/47.
diakses 25-2-2003.
Sub-Bagian Hematologi. Petunjuk diagnosis dan
tatalaksana kasus thalassemia. Jakarta: Bagian Ilmu
Kesehatan Anak FKUI/RSCM; 1997.
Olivieri NF, Brittenham GM, McLaren C, templeton
DM, Cameron RG, Mcleland RA, dkk. Long-term safety
and effectiveness of iron-chelation therapy with
deferiprone for thalassemia major. N Engl J Med 1998;
:417-23.
DOI: http://dx.doi.org/10.14238/sp5.1.2003.16-20
Refbacks
- Saat ini tidak ada refbacks.
##submission.copyrightStatement##
##submission.license.cc.by-nc-sa4.footer##
Email: editorial [at] saripediatri.org
Sari Pediatri diterbitkan oleh Badan Penerbit Ikatan Dokter Anak Indonesia
Ciptaan disebarluaskan di bawah Lisensi Creative Commons Atribusi-NonKomersial-BerbagiSerupa 4.0 Internasional.